CSU Management Updates: 2026 Guidelines and Latest Data

The 2026 international urticaria guideline update represents the first major revision since 2022 and reflects input from more than 200 experts across 59 countries. Among its most clinically consequential changes is the positioning of omalizumab, dupilumab, and remibrutinib together as add-on options for patients with CSU who remain symptomatic despite high-dose antihistamine therapy. This represents a meaningful expansion from prior iterations, in which omalizumab stood largely alone at that step in the algorithm. Within the updated framework, omalizumab is represented by a solid line while dupilumab and remibrutinib appear with dotted lines — a distinction the guideline authors clarify reflects evidence maturity rather than any hierarchy of efficacy. Use of any of these agents may be off-label depending on jurisdiction.

The update also addresses the role of biomarkers in CSU management with notable directness. Despite growing investigation into markers including total IgE levels, thyroid antibodies, and other candidate measures, the guidelines explicitly state that no biomarker has achieved sufficient predictive accuracy for routine clinical use. One relevant clinical signal preserved in the document is the association between low IgE values and attenuated response to omalizumab — a finding that, while not yet actionable as a formal decision rule, can meaningfully inform the therapeutic conversation with individual patients. The absence of a validated predictive biomarker remains one of the more consequential unmet needs in the field, and the guidelines recommend limiting baseline laboratory evaluation to a differential blood count and CRP and/or ESR, with total IgE and anti-TPO antibodies reserved for specialized care settings.

In this video discussion on CSU management updates, Eric Karlin, MD, an allergist/immunologist with Allergy Partners of Hampton Roads in Williamsburg, Virginia, and Steve Dorman, MD, a board-certified allergist/immunologist and clinical research investigator on clinical faculty at the University of Florida College of Medicine, examine the practical implications of these guideline changes. Dorman underscores the historical significance of having 3 agents positioned at the same algorithmic step, noting that clinicians who trained in an era when cyclosporine was the only off-label recourse for antihistamine-refractory CSU will recognize how substantially the landscape has shifted. Both experts emphasize that the visual distinction between the solid and dotted lines in the guideline algorithm is a point of frequent misinterpretation in practice and should be communicated carefully to colleagues evaluating the evidence.